We chose to investigate the role of EGFR in a specific and homogeneous subset of PC patients – those with N0-1 disease-, who are normally not candidates to adjuvant therapy, but at a clinically relevant risk of recurrence. Here, EGFR is linked to pachyonychia congenita.